Given that tigecycline-based combination is recognized as a valuable option to treat tigecycline resistant Acinetobacter baumannii (A.baumannii), we conduct
Background: Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that increases antitumor T-cell responses.We conducted a meta-analysis of rand